2021
Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., & Green, J. A. (2021). First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.CD010383.pub3DOI: 10.1002/14651858.CD010383.pub3
2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903 (Journal article)
Mileshkin, L., Edmondson, R., O'Connell, R. L., Sjoquist, K. M., Andrews, J., Jyothirmayi, R., . . . Friedlander, M. (2019). Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. GYNECOLOGIC ONCOLOGY, 154(1), 29-37. doi:10.1016/j.ygyno.2019.05.007DOI: 10.1016/j.ygyno.2019.05.007
2018
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. (Journal article)
Vergote, I., Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M. K. B., Ehlen, T., . . . MRC CHORUS study investigators. (2018). Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.. The Lancet. Oncology, 19(12), 1680-1687. doi:10.1016/s1470-2045(18)30566-7DOI: 10.1016/s1470-2045(18)30566-7
Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer? (Journal article)
Green, J. A. (2018). Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?. JOURNAL OF THORACIC DISEASE, 10, S3837-S3839. doi:10.21037/jtd.2018.09.52DOI: 10.21037/jtd.2018.09.52
Restoration of conformation of mutant p53 (Journal article)
Green, J. A., Von Euler, M., & Abrahmsen, L. B. (2018). Restoration of conformation of mutant p53. ANNALS OF ONCOLOGY, 29(05), 1325-1328. doi:10.1093/annonc/mdy057DOI: 10.1093/annonc/mdy057
2017
A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer (Journal article)
Pautier, P., Vergote, I., Joly, F., Melichar, B., Kutarska, E., Hall, G., . . . Green, J. A. (2017). A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 27(2), 258-266. doi:10.1097/IGC.0000000000000862DOI: 10.1097/IGC.0000000000000862
Beale, S., Mahon, J., Nevitt, S., Boland, A., Greenhalgh, J., Richardson, M., . . . Green, J. (2017). Atezolizumab for the treatment of people with locally advanced or metastatic non-small lung cancer whose disease has progressed after chemotherapy (ID970).
Greenhalgh, J., Stainthorpe, S., Richardson, M., Duarte, R., Boland, A., Kotas, E., . . . Green, J. (2017). Crizotinib for treating ROS1positive advanced non-small cell lung cancer (D1098).
2016
PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC) (Conference Paper)
Basu, B., Gourley, C., Gabra, H., Vergote, I. B., Brenton, J. D., Abrahmsen, L., . . . Green, J. A. (2016). PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC). In ANNALS OF ONCOLOGY Vol. 27. doi:10.1093/annonc/mdw368.29DOI: 10.1093/annonc/mdw368.29
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial (Journal article)
Sugiyama, T., Okamoto, A., Enomoto, T., Hamano, T., Aotani, E., Terao, Y., . . . Aoki, D. (2016). Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. JOURNAL OF CLINICAL ONCOLOGY, 34(24), 2881-+. doi:10.1200/JCO.2016.66.9010DOI: 10.1200/JCO.2016.66.9010
Despierre, E., Vergote, I., Anderson, R., Coens, C., Katsaros, D., Hirsch, F. R., . . . Jimeno, A. (2016). Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015). TARGETED ONCOLOGY, 11(3), 429. doi:10.1007/s11523-016-0433-xDOI: 10.1007/s11523-016-0433-x
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer (Journal article)
Greenhalgh, J., Dwan, K., Boland, A., Bates, V., Vecchio, F., Dundar, Y., . . . Green, J. A. (2016). First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010383.pub2DOI: 10.1002/14651858.CD010383.pub2
PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC). (Conference Paper)
Gourley, C., Green, J., Gabra, H., Vergote, I., Basu, B., Brenton, J. D., . . . Von Euler, M. (2016). PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.5571DOI: 10.1200/JCO.2016.34.15_suppl.5571
Hypoxic cell sensitization in chemoradiation for cervical cancer (Journal article)
Green, J. A. (2016). Hypoxic cell sensitization in chemoradiation for cervical cancer. TRANSLATIONAL CANCER RESEARCH, 5(2), 196-198. doi:10.21037/tcr.2016.03.05DOI: 10.21037/tcr.2016.03.05
Greenhalgh, J., Aslam, R. W., Mahon, J., Krishan, A., Boland, A., Beale, S., . . . Green, J. (2016). Osimertinib for treating locally advanced or metastatic EGFR and T790M mutation-positive non-small cell lung cancer: Osimertinib for treating locally advanced or metastatic EGFR and T790M mutation-positive non-small cell lung cancer (ID 874).
Greenhalgh, J., Mahon, J., Boland, A., Beale, S., Krishan, A., Abdulla, A., . . . Green, J. (2016). Pembrolizumab for untreated PD-L1 positive metastatic non-small cell lung cancer: Pembrolizumab for untreated PD-L1 positive metastatic non-small cell lung cancer (ID990).
2015
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Journal article)
Despierre, E., Vergote, I., Anderson, R., Coens, C., Katsaros, D., Hirsch, F. R., . . . Jimeno, A. (2015). Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Targeted Oncology, 10(4), 583-596. doi:10.1007/s11523-015-0369-6DOI: 10.1007/s11523-015-0369-6
von Euler, M., Wiman, K. G., Gabra, H., Brenton, J. D., Basu, B., Vergote, I., . . . Green, J. A. (2015). Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer. In CANCER RESEARCH Vol. 75. doi:10.1158/1538-7445.AM2015-CT204DOI: 10.1158/1538-7445.AM2015-CT204
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC). (Conference Paper)
Gourley, C., Gabra, H., Vergote, I., Basu, B., Brenton, J., Von Euler, M., . . . Green, J. (2015). EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.15_suppl.tps5605DOI: 10.1200/jco.2015.33.15_suppl.tps5605
EUTROC PISARRO: PRELIMINARY RESULTS OF PHASE IB STUDY COMBINING APR-246 WITH CHEMOTHERAPY IN PLATINUM SENSITIVE RELAPSED HIGH GRADE SEROUS OVARIAN CARCINOMA(HGSOC) (Journal article)
Gourley, C., Gabra, H., Vergote, I., Basu, B., Brenton, J., von Euler, M., . . . Green, J. (2015). EUTROC PISARRO: PRELIMINARY RESULTS OF PHASE IB STUDY COMBINING APR-246 WITH CHEMOTHERAPY IN PLATINUM SENSITIVE RELAPSED HIGH GRADE SEROUS OVARIAN CARCINOMA(HGSOC). INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25(9), 1368. Retrieved from https://www.webofscience.com/
2014
Alonso-Alconada, L., Muinelo-Romay, L., Madissoo, K., Diaz-Lopez, A., Krakstad, C., Trovik, J., . . . Consortium, E. N. I. T. E. C. (2014). Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, 13. doi:10.1186/1476-4598-13-223DOI: 10.1186/1476-4598-13-223
Systemic chemotherapy: Endometrial cancer (Chapter)
Green, J. A. (2014). Systemic chemotherapy: Endometrial cancer. In Endometrial Cancer: A Comprehensive Clinical and Translational Update (pp. 177-184).
Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study. (Conference Paper)
Okamoto, A., Sugiyama, T., Hamano, T., Kim, J. W., Kim, B. G., Enomoto, T., . . . Ochiai, K. (2014). Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.5507DOI: 10.1200/jco.2014.32.15_suppl.5507
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study (Journal article)
Vergote, I. B., Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., . . . Pujade-Lauraine, E. (2014). Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study. JOURNAL OF CLINICAL ONCOLOGY, 32(4), 320-329. doi:10.1200/JCO.2013.50.5669DOI: 10.1200/JCO.2013.50.5669
Fotopoulou, C., Vergote, I., Mainwaring, P., Bidzinski, M., Vermorken, J. B., Ghamande, S. A., . . . Gabra, H. (2014). Weekly AUC2 carboplatin is inactive in acquired platinum resistant ovarian cancer with or without phenoxodiol, a sensitiser of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Lancet Oncology, 25(1), 160-165. doi:10.1093/annonc/mdt515DOI: 10.1093/annonc/mdt515
2013
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer (Journal article)
Green, J. A., Bates, V., Greenhalgh, J., Boland, A., Jain, P., Dickson, R. C., . . . Vecchio, F. (n.d.). First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. doi:10.1002/14651858.cd010383DOI: 10.1002/14651858.cd010383
MOLECULAR PROFILING OF CIRCULATING TUMOR CELLS LINKS PLASTICITY TO THE METASTATIC PROCESS IN ENDOMETRIAL CANCER. (Journal article)
Alonso Alconada, L., Krakstad, C., Trovik, J., Wik, E., Hapangama, D., Coenegrachts, L., . . . Abal, M. (2013). MOLECULAR PROFILING OF CIRCULATING TUMOR CELLS LINKS PLASTICITY TO THE METASTATIC PROCESS IN ENDOMETRIAL CANCER.. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 23(8). Retrieved from https://www.webofscience.com/
2012
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG (Journal article)
Lindemann, K., Christensen, R. D., Vergote, I., Stuart, G., Izquierdo, M. A., Kærn, J., . . . Kristensen, G. B. (2012). First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.. Annals of oncology : official journal of the European Society for Medical Oncology, 23(10), 2613-2619. doi:10.1093/annonc/mds060DOI: 10.1093/annonc/mds060
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. (Journal article)
Vergote, I. B., Joly, F., Katsaros, D., Coens, C., Reinthaller, A., Hall, M., . . . Pujade-Lauraine, E. (2012). Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.. JOURNAL OF CLINICAL ONCOLOGY, 30(15). doi:10.1200/jco.2012.30.18_suppl.lba5000DOI: 10.1200/jco.2012.30.18_suppl.lba5000
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. (Journal article)
Joly, F., Katsaros, D., Coens, C., Reinthaller, A., Hall, M., Steer, C. B., . . . Pujade-Lauraine, E. (2012). Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(18_suppl), LBA5000. doi:10.1200/jco.2012.30.18_suppl.lba5000DOI: 10.1200/jco.2012.30.18_suppl.lba5000
Towards individualisation of treatment in endometrial cancer (Journal article)
Taylor, S. E., & Green, J. A. (2012). Towards individualisation of treatment in endometrial cancer. BRITISH JOURNAL OF CANCER, 106(10), 1581-1582. doi:10.1038/bjc.2012.140DOI: 10.1038/bjc.2012.140
Randomised phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platin-based chemotherapy for ovarian carcinoma. A Gynaecological Cancer Intergroup and EORTC-GCG study (Journal article)
Vergote, I., Joly, F., Katsaros, D., Coens, C., Reinthaller, A., Hall, M., . . . Pujade-Lauraine, E. (2012). Randomised phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platin-based chemotherapy for ovarian carcinoma. A Gynaecological Cancer Intergroup and EORTC-GCG study. Journal of Clinical Oncology, 30(suppl), LBA 5000.
2011
Ovarian Clear Cell Carcinoma (Chapter)
Ford, A., & Green, J. A. (2011). Ovarian Clear Cell Carcinoma. In Rare and Uncommon Gynecological Cancers (pp. 83-90). Springer Berlin Heidelberg. doi:10.1007/978-3-642-13492-0_7DOI: 10.1007/978-3-642-13492-0_7
Rare and Uncommon Gynecological Cancers (Book)
Reed, N., Green, J. A., Gershenson, D. M., Siddiqui, N., & Connor, R. (Eds.) (2011). Rare and Uncommon Gynecological Cancers. Springer Berlin Heidelberg. doi:10.1007/978-3-642-13492-0DOI: 10.1007/978-3-642-13492-0
The Mutational Profile of Sporadic Epithelial Ovarian Carcinoma (Journal article)
Kalamanathan, S., Bates, V., Lord, R., & Green, J. A. (2011). The Mutational Profile of Sporadic Epithelial Ovarian Carcinoma. ANTICANCER RESEARCH, 31(8), 2661-2668. Retrieved from https://www.webofscience.com/
Poor performance status small cell lung cancer: Who should we treat? (Journal article)
Azam, F., Wong, H., Green, J. A., & Marshall, E. (2011). Poor performance status small cell lung cancer: Who should we treat?. JOURNAL OF CLINICAL ONCOLOGY, 29(15). doi:10.1200/jco.2011.29.15_suppl.e17502DOI: 10.1200/jco.2011.29.15_suppl.e17502
Clinical trials in cancer (Journal article)
Green, J. A. (2011). Clinical trials in cancer. BRITISH JOURNAL OF CANCER, 104(10), 1521-1522. doi:10.1038/bjc.2011.137DOI: 10.1038/bjc.2011.137
Erlotinib for the first line treatment of EGFR-TK mutation positive non-small cell lung cancer (Journal article)
Greenhalgh, J., Bagust, A., Beale, S., Blundell, M., Boland, A., Dundar, Y., . . . Dickson, R. (2011). Erlotinib for the first line treatment of EGFR-TK mutation positive non-small cell lung cancer. Health Technology Assessment.
HPV clearance in cervical cancer (Chapter)
Taylor, S., & Green, J. A. (2011). HPV clearance in cervical cancer. In M. Gultkein (Ed.), Gynaecological Cancer (pp. 4). Istanbul: Turkish Press.
Mutational Profile of sporadic ovarian cancer (Journal article)
Kalamanathan, S., Bates, V., Lord, R., & Green, J. A. (2011). Mutational Profile of sporadic ovarian cancer. Anticancer Res 2011 31 2661-8, 31, 7.
Rare and Uncommon Gynaecological Cancers (Book)
Reed, N., Green, J., Siddiqui, N., & Gershenson, D. (2011). Rare and Uncommon Gynaecological Cancers. New York: Springer.
2010
Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: Single or combination chemotherapy? (Journal article)
Adams, G., Zekri, J. M., Wong, H., & Green, J. A. (2010). Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: Single or combination chemotherapy?. JOURNAL OF CLINICAL ONCOLOGY, 28(15). doi:10.1200/jco.2010.28.15_suppl.5063DOI: 10.1200/jco.2010.28.15_suppl.5063
Clear Cell Tmours of the Ovary (Chapter)
Ford, A., & Green, J. A. (2010). Clear Cell Tmours of the Ovary. In N. Reed, J. A. Green, D. Gershenson, & N. Siddiqui (Eds.), Rare Gynecological Cancers (pp. 8). New York: Springer.
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 47-53. doi:10.3310/hta14suppl1/07DOI: 10.3310/hta14suppl1/07
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 33-39. doi:10.3310/hta14suppl2/05DOI: 10.3310/hta14suppl2/05
Pemetrexed for the treatment of relapsed non-small cell lung cancer (Journal article)
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Davis, H., Dickson, R., . . . Proudlove, N. (2010). Pemetrexed for the treatment of relapsed non-small cell lung cancer. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/erg/reports/1641.pdf
Rare Gynecological Cancers (Book)
Reed, N., Green, J. A., Gershenson, D., & Siddiqui, N. (Eds.) (2010). Rare Gynecological Cancers. New York: Springer.
Retrospective study of travelling times for patients receiving palliative radiotherapy for bone metastases (Journal article)
Bhalla, N., Ibrahim, A., & Green, J. (2010). Retrospective study of travelling times for patients receiving palliative radiotherapy for bone metastases. British Journal of Cancer, 10, A21.
Single agent carboplatin or combination chemotherapy for early stage ovarian cancer (Journal article)
Adams, G., Wong, H., Walking, J., & Green, J. A. (2010). Single agent carboplatin or combination chemotherapy for early stage ovarian cancer. British Journal of Obstetrics and Gynaecology, 117(12, 1459-1467. doi:10.1111/j.1471-0528DOI: 10.1111/j.1471-0528
Single agent or combination chemotherapy for early stage ovarian cancer (Journal article)
Adams, G., Wong, H., & Green, J. A. (2010). Single agent or combination chemotherapy for early stage ovarian cancer. Journal of Clinical Oncology, 28, 5063.
Time to antibiotics in neutropenic sepsis (Journal article)
Ford, A., Sammut, H., Ribton, J., Marshall, E., & Green, J. (2010). Time to antibiotics in neutropenic sepsis. British Journal of Cancer, 10, A20.
pemetrexed for the first line management of locally advanced or metastatic non-small cell lung cancer (Journal article)
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Dundar, Y., Boland, A., . . . Pearson, M. (2010). pemetrexed for the first line management of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(1), 47-54.
2009
Erlotinib for the treatment of relapsed non-small cell lung cancer (Journal article)
McLeod, C., Bagust, A., Boland, A., Hockenhull, J., Dundar, Y., Proudlove, C., . . . Dickson, R. (2009). Erlotinib for the treatment of relapsed non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 13, 41-47. doi:10.3310/hta13suppl1/07DOI: 10.3310/hta13suppl1/07
2008
FANCF promoter hypermethylation as predictor of clinical outcomes in advanced epithelial ovarian cancer (Journal article)
Lim, S., Coens, C., Wong, H., Berns, E., van der Burg, M., Green, J., & Crook, T. (2008). FANCF promoter hypermethylation as predictor of clinical outcomes in advanced epithelial ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 26(15). doi:10.1200/jco.2008.26.15_suppl.5563DOI: 10.1200/jco.2008.26.15_suppl.5563
FANCF promoter hypermethylation as predictor of clinical outcomes in advanced epithelial ovarian cancer. (Journal article)
Lim, S., Coens, C., Wong Dr, H., Berns, E., van der Burg, M., Green, J., & Crook, T. (2008). FANCF promoter hypermethylation as predictor of clinical outcomes in advanced epithelial ovarian cancer.. J Clin Oncol, 26(15_suppl), 5563. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27950496
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer (Journal article)
Lim, S. L., Smith, P., Syed, N., Coens, C., Wong, H., van der Burg, M., . . . Green, J. A. (2008). Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. BRITISH JOURNAL OF CANCER, 98(8), 1452-1456. doi:10.1038/sj.bjc.6604325DOI: 10.1038/sj.bjc.6604325
2007
Hormone therapy in advanced and recurrent endometrial cancer: a systematic review (Journal article)
Decruze, S. B., & Green, J. A. (2007). Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 17(5), 964-978. doi:10.1111/j.1525-1438.2007.00897.xDOI: 10.1111/j.1525-1438.2007.00897.x
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. (Journal article)
Green, J., Dundar, Y., Dodd, S., Dickson, R., & Walley, T. (2007). Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.. The Cochrane database of systematic reviews, (1), CD005574. doi:10.1002/14651858.cd005574.pub2DOI: 10.1002/14651858.cd005574.pub2
A systematic review of hormone therapy in advanced endometrial cancer (Journal article)
DeCruze, B., & Green, J. A. (2007). A systematic review of hormone therapy in advanced endometrial cancer. International Journal of Gynecological Cancer, 17(5), 964-978.
Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration (Journal article)
Humber, C. E., Tierney, J. F., Symonds, R. P., Collingwood, M., Kirwan, J., Williams, C., & Green, J. A. (2007). Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. ANNALS OF ONCOLOGY, 18(3), 409-420. doi:10.1093/annonc/mdl417DOI: 10.1093/annonc/mdl417
DUSP 7 and 8 as prognostic factors in advanced ovarian cancer (Journal article)
Lim, S., van der Burg, M., Crook, T., & Green, J. A. (2007). DUSP 7 and 8 as prognostic factors in advanced ovarian cancer. Proceedings ASCO, 24.
DUSP 7 and 8 as prognostic markers in advanced ovarian Cancer (Journal article)
Lim, S., Crook, T., Syed, N., Smith, P., & Green, J. A. (2007). DUSP 7 and 8 as prognostic markers in advanced ovarian Cancer. American Society fro Clinical Oncology, 25, 5501.
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: A systematic review and economic evaluation (Journal article)
Dundar, Y., Bagust, A., Dickson, R., Dodd, S., Green, J., Haycox, A., . . . Walley, T. (2007). Pemetrexed disodium for the treatment of malignant pleural mesothelioma: A systematic review and economic evaluation. Health Technology Assessment, 11(1). doi:10.3310/hta11010DOI: 10.3310/hta11010
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation (Journal article)
Dundar, Y., Bagust, A., Dickson, R., Dodd, S., Green, J., Haycox, A., . . . Walley, T. (2007). Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 11(1), 1-+. Retrieved from https://www.webofscience.com/
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma (Journal article)
Green, J., Dundar, Y., Dodd, S., Dickson, R., & Walley, T. (2007). Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database of Systematic Reviews, (1). doi:10.1002/14651858.CD005574.pub2DOI: 10.1002/14651858.CD005574.pub2
Pemetrexed disodium in the treatment of malignant mesothelioma (Journal article)
Dundar, Y., Boland, A., Dickson, R., Green, J. A., & Walley, T. (2007). Pemetrexed disodium in the treatment of malignant mesothelioma. Health Technology Assessment, 11(1), 1-80.
Pemetrexed disodium in the treatment of malignant mesothelioma: systematic review (Journal article)
Green, J. A., Dundar, Y., Haycox, A., Bagust, A., Hill, R., Dickson, R., . . . Green, J. A. (2007). Pemetrexed disodium in the treatment of malignant mesothelioma: systematic review. Cochrane Review, 11(1).
2006
Ovarian cancer and ascites: A questionnaire on current management in the United Kingdom (Journal article)
Macdonald, R., Kirwan, J., Roberts, S., Gray, D., Allsopp, L., & Green, J. (2006). Ovarian cancer and ascites: A questionnaire on current management in the United Kingdom. JOURNAL OF PALLIATIVE MEDICINE, 9(6), 1264-1270. doi:10.1089/jpm.2006.9.1264DOI: 10.1089/jpm.2006.9.1264
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865) (Journal article)
Green, J. A., Berns, E. M. J. J., Coens, C., van Luijk, I., Thompson-Hehir, J., van Diest, P., . . . van der Burg, M. E. L. (2006). Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). EUROPEAN JOURNAL OF CANCER, 42(15), 2539-2548. doi:10.1016/j.ejca.2006.06.015DOI: 10.1016/j.ejca.2006.06.015
COX-1 and COX-2 expression in stage I and II invasive cervical carcinoma: relationship to disease relapse and long-term survival (Journal article)
Athavale, R., Clooney, K., O'Hagan, J., Shawki, H., Clark, A. H., & Green, J. A. (2006). COX-1 and COX-2 expression in stage I and II invasive cervical carcinoma: relationship to disease relapse and long-term survival. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 16(3), 1303-1308. doi:10.1111/j.1525-1438.2006.00372.xDOI: 10.1111/j.1525-1438.2006.00372.x
Alterations in the p53 pathway adn prognosis in advanced ovarian cancer: a multifactorial analysis of teh EORTC Gynaaecological Cancer Group (Journal article)
Green, J. A., Berns, E., van der Burg, M., & 8 others. (2006). Alterations in the p53 pathway adn prognosis in advanced ovarian cancer: a multifactorial analysis of teh EORTC Gynaaecological Cancer Group. European Journal of Cancer, 42(15), 2539-2548. doi:10.1016/S0090-8258(03)DOI: 10.1016/S0090-8258(03)
Cytotoxic chemotherapy for advanced or recurrent cervical cancer (Journal article)
Green, J. A., & Lainakis, G. (2006). Cytotoxic chemotherapy for advanced or recurrent cervical cancer. ANNALS OF ONCOLOGY, 17, X230-X232. doi:10.1093/annonc/mdl265DOI: 10.1093/annonc/mdl265
Endometrial Cancer Consensus Conference (Conference Paper)
Kitchener, H., Trimble, E., & Green, J. A. (Eds.) (2006). Endometrial Cancer Consensus Conference. In Endometrial Cancer Consensus Conference (pp. 80). Oxford: Oxford.
Erlotinib in non-small cell lung cancer - Single Technology Appraisal (Report)
Macleod, C., Dickson, R., Whally, T., & Green, J. A. (2006). Erlotinib in non-small cell lung cancer - Single Technology Appraisal. Liverpool: NICE.
Pemetrexed in non-small cell lung cancer: Single technology appraisal (Report)
Macleod, C., Dickson, R., Dundar, Y., Whally, T., & Green, J. A. (2006). Pemetrexed in non-small cell lung cancer: Single technology appraisal. Liverpool: NICE.
Systemic chemotherapy for advanced or recurrent cervical cancer (Journal article)
Green, J. A., & Lainakis, G. (2006). Systemic chemotherapy for advanced or recurrent cervical cancer. Annals of Oncology, 17(10), 230-232.
2005
Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. (Journal article)
Green, J., Kirwan, J., Tierney, J., Vale, C., Symonds, P., Fresco, L., . . . Collingwood, M. (2005). Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix.. The Cochrane database of systematic reviews, (3), CD002225. doi:10.1002/14651858.cd002225.pub2DOI: 10.1002/14651858.cd002225.pub2
Cytotoxic chemotherapy (Ct) for endometrial cancer: A systematic review and meta-analysis. (Conference Paper)
Humber, C., Tierney, J., Collingwood, M., Symonds, P., Kirwan, J., Williams, C., & Green, J. A. (2005). Cytotoxic chemotherapy (Ct) for endometrial cancer: A systematic review and meta-analysis.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 475S). Retrieved from https://www.webofscience.com/
Cytotoxic chemtherapy for endometrial cancer: s systematic review and metaanalysis (Journal article)
Humber, C., Tierney, J., Collingwood, M., Symonds, P., Williams, C., & Green, J. A. (2005). Cytotoxic chemtherapy for endometrial cancer: s systematic review and metaanalysis. Journal Of Clinical Oncology, 23, 1.
FancF in ovarian cancer cells (Journal article)
Green, J. A., Lim, S., & Crook, T. (2005). FancF in ovarian cancer cells. NCRI meeting, 1, 1.
Ovarian cacner ascites : results fo a questionnaire on management (Conference Paper)
Macdonald, R., Allsopp, L., Kirwan, J., Roberts, S., & Green, J. A. (2005). Ovarian cacner ascites : results fo a questionnaire on management. In NCRI Annual Conference (pp. 1). Birmingham: Nature Publishing Group.
Pemetrexed in the treatment of malignant mesothelioma (Report)
Dundar, Y., al, E., & Green, J. A. (2005). Pemetrexed in the treatment of malignant mesothelioma. Liverpool: HTA.
Prognostic markers in advanced ovarian cancer: translational study using samples from the EORTC 55931/OV10 randomsied trial (Conference Paper)
Green, J. A., Lim, S. L., Duffaud, F., Vergote, I., van der Burg, M., & Oza, A. (2005). Prognostic markers in advanced ovarian cancer: translational study using samples from the EORTC 55931/OV10 randomsied trial. In NCRI conference (pp. 1). Birmingham: Nature Publishing Group.
Prognostic value of clincical and molecular markers in advanced ovarian cancer : importance of residual disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 Phase 111 randomized clinical trial (Journal article)
Green, J. A., Duffaud, F., Coens, C., LaFrambroise, A., Vergote, I., Eisenhauer, E., . . . Oza, A. M. (2005). Prognostic value of clincical and molecular markers in advanced ovarian cancer : importance of residual disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 Phase 111 randomized clinical trial. Journal of Clinical Oncology, 23, 1.
2004
Untitled - Response to Vergote letter on early ovarian cancer (Journal article)
Green, J. A. (2004). Untitled - Response to Vergote letter on early ovarian cancer. GYNECOLOGIC ONCOLOGY, 94(2), 607-608. doi:10.1016/j.ygyno.2004.02.027DOI: 10.1016/j.ygyno.2004.02.027
Optimizing Treatment for Cervical Cancer (Journal article)
Green, J. A., & de Barros Lopes, A. (2004). Optimizing Treatment for Cervical Cancer. American Journal of Cancer, 3(4), 215-227. doi:10.2165/00024669-200403040-00002DOI: 10.2165/00024669-200403040-00002
Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix. (Journal article)
Symonds, P., Kirwan, J., Williams, C., Humber, C., Tierney, J., Green, J., & Collingwood, M. (2004). Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix.. The Cochrane database of systematic reviews, (1), CD003918. doi:10.1002/14651858.cd003918.pub2DOI: 10.1002/14651858.cd003918.pub2
Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review (Journal article)
Symonds, R. P., Collingwood, M., Kirwan, J., Humber, C. E., Tierney, J. F., Green, J. A., & Williams, C. (2004). Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review. CANCER TREATMENT REVIEWS, 30(5), 405-414. doi:10.1016/j.ctrv.2003.12.002DOI: 10.1016/j.ctrv.2003.12.002
Optimizing treatment for cervical cancer. The value of chemoradiation (Journal article)
Green, J. A., & De Barros Lopes, A. (2004). Optimizing treatment for cervical cancer. The value of chemoradiation. American Journal of Cancer, 3(4), 215-227.
2003
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit (Journal article)
Green, J. A. (2003). ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit. LANCET, 362(9392), 1333-1334. doi:10.1016/S0140-6736(03)14603-XDOI: 10.1016/S0140-6736(03)14603-X
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit. (Journal article)
Newman, G. (2003). ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.. Lancet (London, England), 362(9392), 1333. doi:10.1016/s0140-6736(03)14602-8DOI: 10.1016/s0140-6736(03)14602-8
A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. (Journal article)
Kirwan, J. M., Symonds, P., Green, J. A., Tierney, J., Collingwood, M., & Williams, C. J. (2003). A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 68(3), 217-226. doi:10.1016/s0167-8140(03)00197-xDOI: 10.1016/s0167-8140(03)00197-x
Re: Adjuvant chemotherapy in patients with early-stage ovarian cancer (Journal article)
Green, J. A. (2003). Re: Adjuvant chemotherapy in patients with early-stage ovarian cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 95(15), 1169. doi:10.1093/jnci/djg004DOI: 10.1093/jnci/djg004
Re: Adjuvant chemotherapy in patients with early-stage ovarian cancer. (Journal article)
Green, J. A. (2003). Re: Adjuvant chemotherapy in patients with early-stage ovarian cancer.. Journal of the National Cancer Institute, 95(15), 1169. doi:10.1093/jnci/djg004DOI: 10.1093/jnci/djg004
Early ovarian cancer - time for a rethink on stage? (Journal article)
Green, J. A. (2003). Early ovarian cancer - time for a rethink on stage?. GYNECOLOGIC ONCOLOGY, 90(2), 235-237. doi:10.1016/S0090-8258(03)00410-4DOI: 10.1016/S0090-8258(03)00410-4
2002
Chemoradiotherapy: A significant advance in the treatment of cervical cancer (Journal article)
Green, J. A., Kirwan, J. M., Tierney, J. F., Symonds, P., Fresco, L., Collingwood, M., & Williams, C. J. (2002). Chemoradiotherapy: A significant advance in the treatment of cervical cancer. BRITISH JOURNAL OF CANCER, 86, S25. Retrieved from https://www.webofscience.com/
Cox-1 and cox-2 expression in invasive cervical cancer: Relationship to prognosis and clinicopathological factors (Journal article)
Athavale, R. D., Clooney, K., O'Hagan, J., Shawki, H., Clark, A. H., & Green, J. A. (2002). Cox-1 and cox-2 expression in invasive cervical cancer: Relationship to prognosis and clinicopathological factors. BRITISH JOURNAL OF CANCER, 86, S43. Retrieved from https://www.webofscience.com/
Treatment of cervical cancer - Reply (Journal article)
Green, J. A. (2002). Treatment of cervical cancer - Reply. LANCET, 359(9303), 358. doi:10.1016/S0140-6736(02)07520-7DOI: 10.1016/S0140-6736(02)07520-7
p53, pRB and EGFR expression in relation to (HPV) subtype in the transformation of cervical intraepithelial neoplasia (CIN). (Journal article)
McLeish, R., Southern, S., Green, J. A., & MacDicken, I. A. (2002). p53, pRB and EGFR expression in relation to (HPV) subtype in the transformation of cervical intraepithelial neoplasia (CIN).. BRITISH JOURNAL OF CANCER, 86, S43. Retrieved from https://www.webofscience.com/
2001
Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis (Journal article)
Green, J. A., Kirwan, J. M., Tierney, J. F., Symonds, P., Fresco, L., Collingwood, M., & Williams, C. J. (2001). Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. LANCET, 358(9284), 781-786. doi:10.1016/S0140-6736(01)05965-7DOI: 10.1016/S0140-6736(01)05965-7
2000
Novel polymerase chain reaction approach for full-coding p53 mutation detection in microdissected archival tumors (Journal article)
Thompson-Hehir, J., Davies, M. P. A., Green, J. A., Halliwell, N., Joyce, K. A., Salisbury, J., . . . Walker, C. (2000). Novel polymerase chain reaction approach for full-coding p53 mutation detection in microdissected archival tumors. DIAGNOSTIC MOLECULAR PATHOLOGY, 9(2), 110-119. doi:10.1097/00019606-200006000-00007DOI: 10.1097/00019606-200006000-00007
1995
Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. (Journal article)
Giles, R. V., Spiller, D. G., Green, J. A., Clark, R. E., & Tidd, D. M. (1995). Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.. Blood, 86(2), 744-754.
1994
Simple cytokeratins in the serum of patients with lung cancer: relationship to cell death. (Journal article)
Pendleton, N., Occleston, N. L., Walshaw, M. J., Littler, J. A., Jack, C. I., Myskow, M. W., & Green, J. A. (1994). Simple cytokeratins in the serum of patients with lung cancer: relationship to cell death.. European journal of cancer (Oxford, England : 1990), 30A(1), 93-96. doi:10.1016/s0959-8049(05)80026-7DOI: 10.1016/s0959-8049(05)80026-7
1993
EXPRESSION OF GLUTATHIONE-S-TRANSFERASE (GST) SUBTYPES IN RESECTED LUNG-TUMORS - RELATIONSHIP TO HISTOLOGICAL TYPE AND PROLIFERATION INDEXES (Journal article)
HATTON, T., PENDLETON, N., BARRACLOUGH, R., & GREEN, J. A. (1993). EXPRESSION OF GLUTATHIONE-S-TRANSFERASE (GST) SUBTYPES IN RESECTED LUNG-TUMORS - RELATIONSHIP TO HISTOLOGICAL TYPE AND PROLIFERATION INDEXES. INTERNATIONAL JOURNAL OF ONCOLOGY, 3(5), 881-886. Retrieved from https://www.webofscience.com/
